Sean Quinlan Davidson, MD
Radiation Oncology · Allentown, PANPI 1588096788
Payments from drug & device makers
Across 43 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$83
- Bayer$74
- Johnson & Johnson$72
- Incyte Corporation$71
- Teleflex LLC$53
- Bristol Myers Squibb$31
- plus $370 from 20 others
What the payments were for
- Food & beverage$754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 3 | $83 |
| Bayer | 4 | $74 |
| Johnson & Johnson | 3 | $72 |
| Incyte Corporation | 5 | $71 |
| Teleflex LLC | 2 | $53 |
| Bristol Myers Squibb | 2 | $31 |
| AstraZeneca | 2 | $27 |
| Foundation Medicine, Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Accuray Incorporated | 1 | $25 |
| Merck | 2 | $25 |
| Amgen | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Tesaro, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Pfizer | 1 | $15 |
| Bioprotect Medical, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $12 |
| Verastem, Inc. | 1 | $12 |
How this compares
$754 in reported general payments places this provider in the 50th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 55 | $1,097 |
| Sucralfate | 11 | $714 |
| Lidocaine Hcl ViscousLidocaine Hcl | 13 | $162 |
| Dexamethasone | 17 | $104 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $75 |
| Prednisone | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Allentown
- David ClumpPittsburgh$3.2M
- Wenyin ShiPhiladelphia$1.1M
- Amit MaityPhiladelphia$1.1M
- Joseph CasterPhiladelphia$1M
- Abigail BermanPhiladelphia$924K
- Mitchell MachtayHershey$741K
- John PlastarasPhiladelphia$538K
- Justin BekelmanPhiladelphia$490K
- James MetzPhiladelphia$458K
- Andy MinnPhiladelphia$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.